Abstract
Langerhans cell histiocytosis is a rare hematologic disorder and patients who fail first-line treatment have a poor prognosis, and require more intensive treatment. We present an infant diagnosed with multisystem Langerhans cell histiocytosis refractory to multimodal therapy who was successfully treated with cyclosporine. Cyclosporine might be an effective alternative drug as nonmyelosuppressive rescue therapy for multiple relapsed-refractory Langerhans cell histiocytosis that has not achieved remission with cladribine and cytarabine therapy.
Keywords:
Langerhans cell histiocytosis; cyclosporine; relapsed-refractory.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cyclosporine / administration & dosage
-
Cyclosporine / adverse effects
-
Cyclosporine / therapeutic use*
-
Drug Resistance, Neoplasm
-
Histiocytosis, Langerhans-Cell / drug therapy*
-
Histiocytosis, Langerhans-Cell / etiology
-
Histiocytosis, Langerhans-Cell / pathology*
-
Histocytochemistry
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Infant
-
Male
-
Radiography, Thoracic
-
Recurrence
-
Retreatment
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Immunosuppressive Agents
-
Cyclosporine